Log in

NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

$9.66
-0.70 (-6.76 %)
(As of 04/2/2020 08:00 AM ET)
Today's Range
$9.58
Now: $9.66
$10.67
50-Day Range
$7.50
MA: $10.77
$13.47
52-Week Range
$7.12
Now: $9.66
$18.98
Volume947,183 shs
Average Volume1.00 million shs
Market Capitalization$518.26 million
P/E Ratio4.56
Dividend YieldN/A
Beta0.43
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More
Vanda Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$227.19 million
Cash Flow$2.02 per share
Book Value$7.70 per share

Profitability

Net Income$115.55 million

Miscellaneous

Employees270
Market Cap$518.26 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.


Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

How has Vanda Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VNDA shares have decreased by 8.9% and is now trading at $9.66. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vanda Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vanda Pharmaceuticals.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Vanda Pharmaceuticals.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported $0.08 EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.04. The biopharmaceutical company earned $60.93 million during the quarter, compared to the consensus estimate of $59.77 million. Vanda Pharmaceuticals had a net margin of 50.86% and a return on equity of 33.33%. View Vanda Pharmaceuticals' earnings history.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $274.55 million.

What price target have analysts set for VNDA?

4 analysts have issued 1 year target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $12.00 to $25.00. On average, they expect Vanda Pharmaceuticals' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price. View analysts' price targets for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (2/26/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view." (7/31/2019)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

News stories about VNDA stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutVanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Array Biopharma (ARRY), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Exelixis (EXEL), Micron Technology (MU) and Sarepta Therapeutics (SRPT).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the following people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $9.66.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $518.26 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe. View additional information about Vanda Pharmaceuticals.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  491 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  909
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel